Roche pays Hansoh $400m upfront in ADC pact worth up to $15bn

Roche has agreed to pay Hansoh Pharmaceutical $400 million upfront for a portfolio of antibody-drug conjugates (ADCs), with up to $15 billion more in milestones, the Chinese drugmaker said on 19 October 2026¹. A further $110 million falls due on the first anniversary of the deal, and Hansoh would also earn tiered royalties on sales¹.

What the deal covers

The agreement brings in two ADCs that Hansoh already has in preclinical development, plus a set of new programmes aimed at targets Roche proposes and built on Hansoh's ADC technology¹. Hansoh will run each programme through Phase 1, after which Roche takes over global development everywhere except Greater China¹. Neither company named the drugs or the diseases involved³.

Hansoh also holds an option to share the cost of global development for two of the programmes. If it takes that route, it becomes eligible for "incremental upside from the commercialization of these two programs"¹.

This is the second time Roche has gone to Hansoh for ADCs. A year earlier it paid $80 million upfront for ex-China rights to HS-20110, an ADC for colorectal cancer and other solid tumours¹². The new pact could be more than 10 times the size of that first agreement². Boris Zaïtra, Roche's head of corporate business development, said the expanded collaboration "marks an important step in advancing our ADC vision"¹.

What it means for the market

The deal adds to a run of Roche licensing agreements with Chinese companies. BioPharma Dive counts it as Roche's sixth China deal since late August, putting the Swiss group well ahead of its peers this year³. pharmaphorum counts seven Chinese deals for Roche in 2026, including a $1.16 billion agreement with Rona Therapeutics for an ALK7-directed RNAi obesity drug and a molecular degrader alliance with Defand Therapeutics worth up to $1 billion².

For buyers and investors, the structure is the point. Roche is paying for access to a discovery engine rather than a single asset, and leaves early clinical risk with the originator until the end of Phase 1¹². That gives Chinese platform companies a template for capturing more of the value they create, while giving big pharma a cheaper route to early pipeline.

Hansoh is already a proven ADC supplier to Western pharma. It licensed two ADCs to GSK in 2023 in agreements worth $1.7 billion and $1.5 billion². One of those, the B7-H3-directed ris-rez, posted a median overall survival of 18.5 months in a Phase 3 trial and a 61% overall response rate in a global Phase 1b study¹. Hansoh lifted R&D spending by 20.7% to 1.7 billion yuan ($253 million) in the first half of the year, supporting more than 40 candidates in over 70 clinical trials¹.

Capital is following the same flow. OrbiMed has raised nearly $3 billion across two funds, including $1 billion for an Asia vehicle, the second major fund recently set up to back biotech opportunities in China³.

Caveats

Almost all of the headline value is contingent on development, regulatory and commercial milestones, and none of the programmes has yet reached human testing under this deal¹. The undisclosed targets and indications make it hard to judge where the ADCs will compete³. The sources also differ on how many China deals Roche has signed this year, depending on the period counted²³. Data from the GSK-partnered B7-H3 ADC in small cell lung cancer are due at the ESMO congress².